Profile data is unavailable for this security.
About the company
SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis.
- Revenue in GBP (TTM)161.65k
- Net income in GBP-2.88m
- Incorporated2015
- Employees11.00
- LocationSkinBioTherapeutics PLCThe Core, Newcastle HelixNEWCASTLE UPON TYNE NE4 5TFUnited KingdomGBR
- Phone+44 191 495 7325
- Websitehttps://www.skinbiotherapeutics.com/
Mergers & acquisitions
| Acquired company | SBTX:LSE since announced | Transaction value |
|---|---|---|
| Bio-Tech Solutions Ltd | 42.22% | 1.63m |
| Dermatonics Ltd | 8.47% | 3.73m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LungLife AI Inc | 23.04k | -3.55m | 7.32m | 15.00 | -- | 0.3556 | -- | 317.62 | -0.1334 | -0.1334 | 0.0009 | 0.2473 | 0.0027 | -- | 2.90 | 1,536.09 | -42.18 | -- | -47.78 | -- | 100.00 | -- | -15,403.45 | -- | -- | -- | 0.0259 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.70m | 7.53m | 67.00 | -- | 9.49 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.002 | 0.00 | -- | -- | -- | -146.70 | -144.15 | -157.81 | -167.75 | -- | -- | -- | -- | -- | -0.45 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Synairgen plc | 0.00 | -6.92m | 9.38m | 36.00 | -- | 0.9751 | -- | -- | -0.0344 | -0.0344 | 0.00 | 0.0475 | 0.00 | -- | -- | 0.00 | -47.18 | -54.01 | -54.24 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| IXICO PLC | 6.00m | -1.87m | 11.12m | 89.00 | -- | 0.578 | -- | 1.85 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| OptiBiotix Health PLC | 569.00k | -2.98m | 12.00m | 5.00 | -- | 1.63 | -- | 21.09 | -0.0317 | -0.0317 | 0.0061 | 0.0752 | 0.0634 | 1.35 | 1.07 | 113,800.00 | -33.25 | 16.82 | -34.85 | 17.52 | 47.98 | 53.03 | -524.43 | 183.49 | 5.36 | -2.03 | 0.00 | 100.14 | 40.92 | 4.60 | -178.82 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.55m | 16.37m | 7.00 | -- | -- | -- | -- | -0.0189 | -0.0189 | 0.00 | -0.0061 | 0.00 | -- | -- | 0.00 | -852.34 | -115.31 | -- | -153.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -12.76 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.18m | 21.38m | 17.00 | -- | 6.68 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0023 | 0.00 | -- | -- | 0.00 | -77.79 | -82.19 | -85.95 | -95.97 | -- | -- | -- | -- | -- | -19.94 | 0.4794 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Shield Therapeutics PLC | 20.88m | -36.17m | 23.07m | 73.00 | -- | 42.64 | -- | 1.10 | -0.0477 | -0.0477 | 0.0274 | 0.0007 | 0.4723 | 4.06 | 1.69 | 286,068.50 | -81.80 | -56.68 | -136.41 | -67.44 | 34.65 | 52.20 | -173.18 | -365.89 | 0.8968 | -15.29 | 0.9736 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
| Arecor Therapeutics PLC | 4.90m | -8.67m | 28.88m | 50.00 | -- | 4.61 | -- | 5.90 | -0.283 | -0.283 | 0.16 | 0.1658 | 0.3213 | -- | 1.67 | 97,980.00 | -56.84 | -- | -89.06 | -- | -- | -- | -176.89 | -- | 1.27 | -- | 0.0523 | -- | 90.30 | -- | 7.62 | -- | -- | -- |
| Sareum Holdings Plc | 0.00 | -3.42m | 32.43m | 5.00 | -- | 13.28 | -- | -- | -0.0422 | -0.0422 | 0.00 | 0.0196 | 0.00 | -- | -- | -- | -142.89 | -81.13 | -209.37 | -96.44 | -- | -- | -- | -23,877.73 | -- | -163.36 | -- | -- | -- | -- | -7.14 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 36.26m | 11.00 | -- | 8.28 | -- | 224.34 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.38m | 38.00m | 8.00 | -- | 3.05 | -- | -- | -0.0088 | -0.0088 | 0.00 | 0.0249 | 0.00 | -- | -- | 0.00 | -29.11 | -- | -30.18 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.11 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Yarra Investment Management Ltd.as of 30 Nov 2023 | 13.82m | 6.05% |
| Unicorn Asset Management Ltd.as of 08 Apr 2024 | 7.89m | 3.46% |
| Evelyn Partners Investment Management LLPas of 31 Dec 2023 | 1.46m | 0.64% |
